Blue Water Vaccines, a Cincinnati, OH-based company developing a universal flu vaccine based on technology developed at the University of Oxford, raised $7m in seed funding.
The round was led by CincyTech, with participation from CincyTech-affiliated private investors.
The financing follows a preclinical study which offered early validation of the company’s novel approach to vaccine design.
The capital will now finance an additional preclinical study, followed by a Phase 1 trial targeted for 2020.
Led by Joseph Hernandez, CEO, Blue Water Vaccines uses technology developed by scientists at the University of Oxford to develop a single vaccine that protects against all influenza strains.
The company secured exclusive rights to the vaccine from Oxford University Innovation, the research commercialisation company of the University of Oxford, UK.
FinSMEs
09/07/2019